The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A prospective, open labelled study. - Effects of anabolic therapies on PTH circadian rhythm & sensitivity

Royal Liverpool University hospital0 个研究点目标入组 100 人开始时间: 2005年12月12日最近更新: 2019年11月25日

试验速览

暂无简介。

•1.Postmenopausal women(no spontaneous menses for 2years or more) >55 years with reduced BMD (T score < -1.0 on DEXA scan)
•2.Men with reduced BMD (T score <-1.0 on DEXA)
•3.Adult Growth Hormone Deficiency (defined as a peak GH response of less than 9mU/litre (3 microg/litre) to hypoglycaemia
•(blood glucose <2.2mmol/litre) induced during an insulin stress test).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Abnormal PTH, calcium, phosphate, vitamin D (<10 ng/ml), testosterone, thyroid function (except stable thyroxine replacement) on baseline testing
•Unstable angina
•NYHA heart failure grades III and IV
•Liver disease (liver function tests >3 times upper limit of normal)
•Renal disease (Creatinine > 150µmol/l)
•Patients with nephrocalcinosis (renal stone )
•Malignant carcinomas, tumour activity, excluding basal cell carcinoma of skin
•Previous vertebral or hip fracture
•Ongoing treatment with corticosteroids, bisphosphonates, diuretics, calcium and vitamin D (pharmacological doses)
•Women on HRT
•Previous venous thromboembolism
•Patients with uncontrolled or accelerated hypertension
•Patients with Phenylketonuria
•Patients who refuse to participate.

发起方